Targeting indolent non-Hodgkin lymphoma
Sign Up to like & getrecommendations! Published in 2017 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2017.1303374
Abstract: ABSTRACT Introduction: Due to recent advancements in the understanding of the molecular pathogenesis of B-cell malignancies, there has been an explosion of innovative agents in development. The purpose of this review is to efficiently summarize… read more here.
Keywords: lymphoma; hodgkin lymphoma; indolent non; non hodgkin ... See more keywords
Persistent symptoms of fatigue, neuropathy and role‐functioning impairment among indolent non‐Hodgkin lymphoma survivors: A longitudinal PROFILES registry study
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18139
Abstract: Little is known about the long‐term health‐related quality of life (HRQoL) and persistence of symptoms among patients with indolent non‐Hodgkin lymphoma (iNHL). This large population‐based longitudinal study therefore investigated the long‐term HRQoL and persistence of… read more here.
Keywords: hodgkin lymphoma; persistent symptoms; non hodgkin; functioning impairment ... See more keywords
Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-4575
Abstract: Purpose: N-803 is an IL15 receptor superagonist complex, designed to optimize in vivo persistence and trans-presentation, thereby activating and expanding natural killer (NK) cells and CD8+ T cells. Monoclonal antibodies (mAbs) direct Fc receptor–bearing immune… read more here.
Keywords: il15 receptor; non hodgkin; patients indolent; receptor ... See more keywords
Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021006083
Abstract: Key Points Zanubrutinib is a second-generation Bruton's tyrosine kinase inhibitor with a favorable safety and tolerability profile. Zanubrutinib demonstrated antitumor activity in patients with relapsed/refractory marginal zone and follicular lymphomas. read more here.
Keywords: non hodgkin; relapsed refractory; indolent non; refractory indolent ... See more keywords
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco-25-00668
Abstract: Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL). Here, we report updated clinical outcomes from ZUMA-5 in 159 enrolled patients with R/R indolent… read more here.
Keywords: non hodgkin; axi cel; indolent non; axicabtagene ciloleucel ... See more keywords
Extending Treatment Intervals of R-CHOP Therapy Might Be Acceptable for Some Patients with Non-indolent Non-Hodgkin's B-cell Lymphoma.
Sign Up to like & getrecommendations! Published in 2022 at "Acta medica Okayama"
DOI: 10.18926/amo/63204
Abstract: R-CHOP therapy is generally performed every 3 weeks. We investigated the effects of extending the interval of R-CHOP therapy for > 1 week on the prognoses of patients with non-indolent non-Hodgkin's B-cell lymphoma. Among the… read more here.
Keywords: non hodgkin; non indolent; therapy; patients non ... See more keywords